Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Health system

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44336   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    3,945 result(s) found for: Health system. Displaying page 1 of 198.
    1  2  3  4  5  6  7  8  9  Next» Last»»
    EudraCT Number: 2008-001185-91 Sponsor Protocol Number: FMPS–30094 Start Date*: 2008-06-06
    Sponsor Name:AZIENDA OSPEDALIERA SENESE
    Full Title: Central randomized, double-blind, crossover, multicenter clinical trial of Betametasone and placebo in children with ataxia teleangectasia
    Medical condition: ataxia teleangectasia
    Disease: Version SOC Term Classification Code Term Level
    9.1 10029205 Nervous system disorders SOC
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2011-001556-11 Sponsor Protocol Number: 1058 Start Date*: 2011-05-23
    Sponsor Name:IRCCS FONDAZIONE STELLA MARIS
    Full Title: Decline of mentale functions in adults with Down Syndrome: clinical and experimental study on the effects of treatment with fluoxetine and of cognitive and physical training.
    Medical condition: Adults (over 30 years) with Down Syndrome.
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029205 - Nervous system disorders 10040442 Severe imbecility LLT
    14.1 10029205 - Nervous system disorders 10029205 Nervous system disorders SOC
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2014-003034-42 Sponsor Protocol Number: ALX0061-C203 Start Date*: 2015-05-08
    Sponsor Name:Ablynx NV
    Full Title: A Phase II Multicenter, Open-Label Extension Study Assessing the Long-Term Efficacy and Safety of Subcutaneous ALX-0061 in Subjects with Moderate to Severe Rheumatoid Arthritis who Have Completed O...
    Medical condition: Rheumatoid Arthritis (RA)
    Disease: Version SOC Term Classification Code Term Level
    18.1 10021428 - Immune system disorders 10021428 Immune system disorders SOC
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Completed) DE (Completed) ES (Completed) BG (Completed) BE (Completed)
    Trial results: View results
    EudraCT Number: 2021-000070-29 Sponsor Protocol Number: 74668 Start Date*: 2022-09-15
    Sponsor Name:VU University Medical Center
    Full Title: A Proof-of-Concept Study to Explore the Potential Efficacy of Deferiprone in Patients With Pelizaeus-Merzbacher disease (PMD)
    Medical condition: Pelizaeus-Merzbacher disease
    Disease:
    Population Age: Infants and toddlers, Children, Under 18 Gender: Male
    Trial protocol: NL (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2020-003874-30 Sponsor Protocol Number: MS700568_0158 Start Date*: 2021-02-03
    Sponsor Name:Merck Healthcare KGaA
    Full Title: A 2-year follow-up study to assess cognition and health-related quality of life in participants with highly-active relapsing multiple sclerosis, having participated in the CLARIFY MS trial
    Medical condition: Highly-active relapsing multiple sclerosis
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029205 - Nervous system disorders 10029205 Nervous system disorders SOC
    20.1 10029205 - Nervous system disorders 10028245 Multiple sclerosis PT
    21.0 10029205 - Nervous system disorders 10080700 Relapsing multiple sclerosis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Completed) HU (Completed) SK (Completed) DK (Completed) AT (Completed) FR (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2014-003033-26 Sponsor Protocol Number: ALX0061-C201 Start Date*: 2015-03-23
    Sponsor Name:Ablynx NV
    Full Title: A Phase IIb Multicenter, Randomized, Double-blind, Placebo-Controlled Dose-Range Finding Study of ALX-0061 Administered Subcutaneously in Combination with Methotrexate, in Subjects with Moderate to...
    Medical condition: Rheumatoid Arthritis (RA)
    Disease: Version SOC Term Classification Code Term Level
    18.0 10021428 - Immune system disorders 10021428 Immune system disorders SOC
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) HU (Completed) CZ (Completed) DE (Completed) ES (Completed) BG (Completed)
    Trial results: View results
    EudraCT Number: 2014-003012-36 Sponsor Protocol Number: ALX0061-C202 Start Date*: 2015-03-23
    Sponsor Name:Ablynx NV
    Full Title: A Phase IIb Multicenter, Randomized, Double-blind Study of ALX-0061 Administered Subcutaneously as Monotherapy, in Subjects with Moderate to Severe Rheumatoid Arthritis who are Intolerant to Methot...
    Medical condition: Rheumatoid Arthritis (RA)
    Disease: Version SOC Term Classification Code Term Level
    18.0 10021428 - Immune system disorders 10021428 Immune system disorders SOC
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) DE (Completed) HU (Completed) CZ (Completed) ES (Completed) BG (Completed)
    Trial results: View results
    EudraCT Number: 2017-003536-36 Sponsor Protocol Number: ACP-103-046 Start Date*: 2018-09-03
    Sponsor Name:ACADIA Pharmaceuticals Inc.
    Full Title: A Phase 3b, Multicenter, Randomized, Double-blind, Placebo-controlled, Safety Study of Pimavanserin Therapy in Adult and Elderly Subjects With Neuropsychiatric Symptoms Related to Neurodegenerativ...
    Medical condition: Neuropsychiatric Symptoms Related to Neurodegenerative Disease
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029205 - Nervous system disorders 10029205 Nervous system disorders SOC
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Completed) BG (Completed) RO (Completed)
    Trial results: View results
    EudraCT Number: 2008-000833-23 Sponsor Protocol Number: BACLOFENE INTRATECALE Start Date*: 2008-02-26
    Sponsor Name:AZIENDA OSPEDALIERA ISTITUTI CLINICI DI PERFEZIONAMENTO DI MILANO
    Full Title: Efficacy evaluation of oral baclofen treatment versus intrathecal baclofen in children with dystonic cerebral palsy
    Medical condition: Dystonic or spastic dystonic cerebral palsy
    Disease: Version SOC Term Classification Code Term Level
    9.1 10029205 SOC
    9.1 10008129 PT
    9.1 10021740 LLT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2011-004078-26 Sponsor Protocol Number: 10/143/FRE Start Date*: 2011-11-30
    Sponsor Name:Brighton & Sussex University Hospitals NHS Trust
    Full Title: A double blind placebo controlled randomised trial to study the effects of birch pollen specific immunotherapy (BP-SIT) on the symptoms of the oral allergy syndrome in adult patients.
    Medical condition: Oral allergy syndrome
    Disease: Version SOC Term Classification Code Term Level
    15.1 10021428 - Immune system disorders 10021428 Immune system disorders SOC
    15.1 10021428 - Immune system disorders 10001708 Allergic conditions HLGT
    15.1 10021428 - Immune system disorders 10068355 Oral allergy syndrome PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2008-007967-18 Sponsor Protocol Number: MK0462-088 Start Date*: 2009-06-25
    Sponsor Name:CASA DI CURA PRIVATA S.RAFFAELE - PISANA
    Full Title: A Double-Blind, Placebo Crontrolled, Prallel Group Study to Compare the Efficacy of Rizatriptan 10 mg Iyophilized wafer in the Acute Treatment of Migraine in Patients with Unilateral Trigeminal Aut...
    Medical condition: not applicable
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029205 - Nervous system disorders 10029205 Nervous system disorders SOC
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2017-004439-36 Sponsor Protocol Number: ACP-103-047 Start Date*: 2018-09-03
    Sponsor Name:ACADIA Pharmaceuticals Inc.
    Full Title: A 52-Week Open-Label Extension Study of Pimavanserin in Adult and Elderly Subjects With Neuropsychiatric Symptoms Related to Neurodegenerative Disease
    Medical condition: Neuropsychiatric Symptoms Related to Neurodegenerative Disease
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029205 - Nervous system disorders 10029205 Nervous system disorders SOC
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Completed) BG (Completed) RO (Completed)
    Trial results: (No results available)
    EudraCT Number: 2018-004145-16 Sponsor Protocol Number: Z7219K01 Start Date*: 2019-07-24
    Sponsor Name:Zambon SpA
    Full Title: A 12-weeks, multicentre, randomized, double-blind, placebo-controlled, exploratory, pilot study to evaluate the safety and efficacy of safinamide 200 mg once daily, as add-on therapy, in patients w...
    Medical condition: Parkinsonian variant of Multiple System Atrophy
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029205 - Nervous system disorders 10064060 Multiple system atrophy PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2015-003282-29 Sponsor Protocol Number: 109MS311 Start Date*: 2016-06-17
    Sponsor Name:Biogen Idec Research Limited
    Full Title: A Multicenter Extension Study to Determine the Long-Term Safety and Efficacy of BG00012 in Pediatric Subjects With Relapsing-Remitting Multiple Sclerosis
    Medical condition: Relapsing Remitting Multiple Sclerosis (RRMS)
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029205 - Nervous system disorders 10029205 Nervous system disorders SOC
    20.0 10029205 - Nervous system disorders 10063399 Relapsing-remitting multiple sclerosis PT
    Population Age: Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: DE (Completed) BE (Completed) CZ (Completed) LV (Completed) BG (Completed)
    Trial results: View results
    EudraCT Number: 2014-004562-22 Sponsor Protocol Number: 109MS416 Start Date*: 2015-06-10
    Sponsor Name:Biogen Idec Research Limited
    Full Title: A Multicenter, Treatment-Blind Phase 3b Study to Evaluate Whether 6-Week Up-Titration in Tecfidera® Dose is Effective in Reducing the Incidence of Gastrointestinal Adverse Events in Patients with M...
    Medical condition: Multiple Sclerosis
    Disease: Version SOC Term Classification Code Term Level
    17.1 10029205 - Nervous system disorders 10029205 Nervous system disorders SOC
    17.1 10029205 - Nervous system disorders 10063399 Relapsing-remitting multiple sclerosis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Prematurely Ended) CZ (Completed) HU (Prematurely Ended) IT (Prematurely Ended) DE (Completed)
    Trial results: View results
    EudraCT Number: 2013-004503-39 Sponsor Protocol Number: IG1104 Start Date*: 2015-01-28
    Sponsor Name:Instituto Grifols, S.A.
    Full Title: A multicenter, prospective, randomized, placebo-controlled, double-blind, parallel-group clinical trial to assess the efficacy and safety of Immune Globulin Intravenous (Human) Flebogamma® 5% DIF...
    Medical condition: Patients with Post-polio syndrome
    Disease: Version SOC Term Classification Code Term Level
    17.0 10029205 - Nervous system disorders 10036239 Post polio syndrome PT
    17.0 10029205 - Nervous system disorders 10029205 Nervous system disorders SOC
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed) DE (Prematurely Ended) DK (Prematurely Ended) NL (Completed) ES (Prematurely Ended) PL (Prematurely Ended) RO (Prematurely Ended) HU (Prematurely Ended) CZ (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2004-001098-25 Sponsor Protocol Number: NAC-E-21 Start Date*: 2004-08-23
    Sponsor Name:Zambon SA
    Full Title: N-Acetylcisteine (NAC) effect on the inmunologycal system
    Medical condition: Postmenopausal health woman aged more than 50 years
    Disease:
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: ES (Completed)
    Trial results: View results
    EudraCT Number: 2022-002987-57 Sponsor Protocol Number: AL002-LTE Start Date*: 2023-03-09
    Sponsor Name:Alector Inc.
    Full Title: A Multicenter, Long-Term Extension Study to Evaluate the Safety, Tolerability, and Efficacy of AL002 in Participants with Alzheimer’s Disease
    Medical condition: Early Alzheimer's Disease
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029205 - Nervous system disorders 10029205 Nervous system disorders SOC
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Trial now transitioned) NL (Trial now transitioned) DE (Trial now transitioned) ES (Ongoing) PL (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2013-002654-75 Sponsor Protocol Number: EVP-6124-026 Start Date*: 2015-08-04
    Sponsor Name:Forum Pharmaceuticals Inc.
    Full Title: A 26-Week Extension Study of the Safety and Clinical Effects of EVP-6124 in Subjects with Alzheimer’s Disease Currently or Previously Receiving an Acetylcholinesterase Inhibitor Medication
    Medical condition: Alzheimer’s Disease
    Disease: Version SOC Term Classification Code Term Level
    18.0 10029205 - Nervous system disorders 10001896 Alzheimer's disease LLT
    18.0 10029205 - Nervous system disorders 10029205 Nervous system disorders SOC
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended) BE (Prematurely Ended) GB (Prematurely Ended) ES (Prematurely Ended) IT (Prematurely Ended) NL (Completed) CZ (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2013-001656-35 Sponsor Protocol Number: 109MS408 Start Date*: 2014-04-07
    Sponsor Name:Biogen Idec Research Limited
    Full Title: A Multicenter, Open-Label Study Evaluating the Effectiveness of Oral Tecfidera™ (Dimethyl Fumarate) on MS Disease Activity and Patient-Reported Outcomes in Subjects with Relapsing-Remitting Multipl...
    Medical condition: Relapsing-Remitting Multiple Sclerosis
    Disease: Version SOC Term Classification Code Term Level
    19.0 10029205 - Nervous system disorders 10029205 Nervous system disorders SOC
    19.0 10029205 - Nervous system disorders 10063399 Relapsing-remitting multiple sclerosis PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: AT (Completed) HU (Completed) BE (Completed) PT (Completed) IT (Completed) CZ (Completed) SK (Completed) ES (Completed) SI (Completed) FR (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  4  5  6  7  8  9  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Thu May 15 23:56:21 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA